CONFERENCE DAY TWO
7:15 am Check-in & Morning Coffee
8:15 am Chair’s Opening Remarks
Advancing Bifunctionals Towards the First Approval with Clinical Data from Leaders in Clinic
8:30 am Driving Progress for a Differentiated Oral Oncology Degrader
9:00 am Clinical Activity of NX-5948 in CLL & NHL: A First-in-Class BTK Degrader
9:30 am Enabling Insights into Molecular Glue MoA Toward Design of Potent & Selective CK1a Degraders
10:00 am Teaching CRBN New Tricks
10:30 am Morning Break & Networking
Novel Target & Pathway Identification & Selection to Unearth
New Molecular Glues
11:30am: Novel Molecular Glue Targets
Download the Full Event Guide to see session details
Gregory Michaud, Director, Novartis
12:00pm: First-in-Class Molecular Glue Degrader of an RNA-Binding Protein to Treat BRAF-Mutant Tumor
Download the Full Event Guide to see session details
Yong Cang, Chief Scientific Officer & Co-Founder, Degron Therapeutics
12:00pm: Presentation Brought to You by WuXi Apptec
Download the Full Event Guide to see session details
Talk details TBC
12:50pm: Rapid Expression of E3 Ubiquitin Ligases to Accelerate Target Protein Degradation Studies
- The eProtein Discovery System revolutionizes cell-free protein production, allowing researchers to obtain high-quality proteins in just 2 days.
- Showcasing a streamlined process for rapid expression and purification screening, which helps define the optimal conditions for producing several common E3 ubiquitin ligases at high yields
- By pinpointing the ideal expression parameters, researchers can swiftly scale up protein production the next day, thereby accelerating drug discovery efforts.
Michael Chen, Chief Executive Officer, Nuclera
1:00pm: Networking Lunch Break
Unravelling MOA & Optimizing Binding of Selective Degraders
2:00pm: Discovery of Novel Monovalent Degraders of SMARCA2/4
Download the Full Event Guide to see session details
Joachim Rudolph, Senior Fellow, Genentech
2:30pm: Degrading Hard to Drug Disease Causing Extracellular Proteins
Download the Full Event Guide to see session details
Shyra Gardai, Chief Scientific Officer, EpiBiologics
3:00pm: Afternoon Networking Break
CLOSING KEYNOTE PLENARY SESSION
3:30 pm Structural, Biochemical, Biophysical, & Computational Characterization of KT-474
Synopsis
- Heterobifunctional degrader KT-474 induces ternary complex formation, ubiquitination, and degradation of IRAK4
- Ternary complex structure shows novel protein-protein interactions important for ternary complex formation and stability
- Structural explanations for cooperativity and selectivity will be discussed
Preparing for the Future: Accelerating Strategy, Partnering & Investment for TPD & Beyond
4:00 pm A review of the TPD Deals & Companies Landscape
Synopsis
- An overview of the commercial landscape
- The 2024 deals & companies landscape
- Investment into novel degrader technologies
4:10 pm Panel Discussion: Lessons Learned from a Major Strategic Partnership Deal for a Platform
4:45 pm Introduction: A Review of the Current Trends in Asset Deals
Synopsis
- 10-minute high level overview of the past and recent deals for early stage and later stage assets in TPD & Induced Proximity, for PROTACs, Molecular Glues, and beyond